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Abstract
Introduction
The Palestinian Ministry of Health (MOH) started a routine rotavirus immunization program
with ROTARIX in May 2016, with support for vaccine procurement and introduction provided
through a global development organization. In 2018, financial responsibility for rotavirus vac-
cine procurement was transferred to the Palestinian government, which elected to shift to
ROTAVAC vaccine because of its lower price per dose. This study aims to assess the cost,
impact, and cost-effectiveness of rotavirus vaccination, specifically evaluating the economic
implications of the change in vaccine product, accounting for the different characteristics of
each rotavirus vaccine used.
Methods
We conducted primary and secondary data collection to assess the introduction, procure-
ment, supply chain, and service delivery costs related to each vaccine. We used the UNI-
VAC model to project costs and benefits of rotavirus vaccination over a 10-year period
comparing the use of ROTARIX versus no vaccination; ROTAVAC versus no vaccination;
and ROTAVAC versus ROTARIX. We undertook scenario and probabilistic analyses to cap-
ture uncertainty in some of the study parameters. We used a 3% discount rate, and all costs
are in 2018 US$.
Results
The cost to deliver one dose was lower for ROTAVAC than ROTARIX (US$2.36 versus
$2.70), but the total cost per course, excluding vaccine cost, favored ROTARIX ($7.09 ver-
sus $5.39). Both vaccines had high probability of being cost-effective interventions in
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Palestine compared to no vaccine. Because of lower vaccination program costs for ROTA-
VAC, however, switching from ROTARIX to ROTAVAC was cost-saving.
Conclusion
National decision-makers should consider systematically assessing multiple criteria beyond
vaccine price when comparing the health and economic value of several products in order to
fully account for all characteristics including product presentation, number of doses per
course, cold chain volume, cost of delivery, and wastage.
Introduction
Despite a decreasing trend in diarrhea mortality over the 2005 to 2015 period, rotavirus
remains responsible for 200,000 deaths in children under five years of age annually and mil-
lions of cases of illness requiring treatment and care [1–3]. The World Health Organization
(WHO) recommends rotavirus vaccination in all national immunization programs and the
vaccine is currently used by more than 95 countries worldwide [4,5]. For almost a decade,
countries had to choose between two available rotavirus vaccines, ROTARIX1 (a registered
trademark of GlaxoSmithKline Biologicals SA, used under license by GlaxoSmithKline Inc.)
and RotaTeq1 (a registered trademark of Merck & Co., Inc.). In 2018, WHO prequalified
two additional rotavirus vaccines, ROTAVAC1 (Bharat Biotech International Limited) and
ROTASIIL1 (Serum Institute of India), enabling procurement by international agencies and
broadening country choice [6].
The Middle Eastern and North African region has experienced a persistent burden of rota-
virus infection, responsible for up to 45% of diarrhea-related hospitalizations in the region
between 2010 and 2015 [7,8]. Before rotavirus vaccine introduction, the Palestinian territories
of Gaza and West Bank reported 25% prevalence rates of diarrheal illnesses among children
younger than six months of age, the highest in the region [9]. As of 2018, 14 out of the 22 coun-
tries of the WHO Eastern Mediterranean Region (EMRO) had introduced rotavirus vaccine
[5]. The Palestinian Ministry of Health (MOH) started its routine rotavirus immunization pro-
gram in May 2016, with support for vaccine procurement and introduction provided through
the Rostropovich-Vishnevskaya Foundation (RVF), a global development organization. After
one year of program implementation, 97.4% of the targeted birth cohort had been immunized
with two doses of ROTARIX. Over the period 2015 to 2017, outpatient cases of diarrhea in chil-
dren under five in Gaza dropped by 27%, while the prevalence of rotavirus in diarrheal stool
samples tested at a large pediatric hospital in Bethlehem, West Bank, decreased by 65% [10].
In 2018, financial responsibility for rotavirus vaccine procurement was transferred to the
Palestinian government, which elected to shift to ROTAVAC vaccine because of its lower
price per dose. While ROTAVAC’s lower price per dose was a key driver in this decision, this
consideration has to be balanced against other characteristics, such as the need for three doses
for a complete immunization regimen with ROTAVAC rather than two with ROTARIX.
ROTAVAC also comes in 5- and 10-dose vials compared to the single-dose vial for ROTARIX,
leading to a likelihood of higher wastage rates with ROTAVAC. In addition, this balance must
account for any potential cost implications of delivering the vaccine due to differences in
presentation, storage conditions, and stability compared to ROTARIX. As shown previously,
because of differing product characteristics, the choice of rotavirus vaccine product has
several implications, particularly in terms of budget impact, cost, and cost-effectiveness [11].
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This study aims to assess the cost, impact, and cost-effectiveness of rotavirus vaccination in
Palestine, specifically evaluating the economic implications of the change in vaccine product.
The primary differences examined between products includes the number of doses, price per
dose, wastage, in-country logistics and the health system cost per dose. This information can
be used by other countries that may be considering a product switch and other stakeholders
interested in the cost implications of such a switch.
Materials and methods
We projected costs and benefits of rotavirus vaccination over a 10-year period comparing the
use of ROTARIX versus no vaccination and the use of ROTAVAC versus no vaccination. Fur-
ther, we conducted a head-to-head comparison of the costs and benefits of the switch (ROTA-
VAC versus ROTARIX). In this analysis, we focused on the 5-dose rather than the 10-dose
presentation of ROTAVAC, as this was Palestine’s preferred choice. We calculated our main
study outcome, the incremental cost-effectiveness ratio, which represents the cost required to
avert one disability-adjusted life-year (DALY). We used a 3% discount rate, and all costs are in
2018 US$.
To measure the benefits of rotavirus vaccination, we calculated outcomes such as the
number of rotavirus cases, outpatient visits, hospitalizations, deaths, and DALYs averted by
vaccination and also the same outcomes without vaccination. Our population of interest
was children under five years old. When infected with rotavirus, sick children can experi-
ence a non-severe or a severe episode of rotavirus gastroenteritis (RVGE). We assumed chil-
dren with non-severe episodes will either seek treatment in an outpatient setting or not, and
will then recover. In contrast, children with severe episodes could seek treatment in an out-
patient and/or inpatient setting or not, and would then either recover or die. Incidence rates
for each disease event were applied to the under-five population to reflect the burden of rota-
virus disease.
Model
We used the UNIVAC model version 1.3.41 (www.paho.org/provac-toolkit). UNIVAC is an
excel-based static cohort model developed through a collaboration between the Pan American
Health Organization and the London School of Hygiene and Tropical Medicine. UNIVAC
is a follow-on to the TRIVAC tool, the methods of which have been described elsewhere [12].
UNIVAC generates transparent and conservative estimates of projected impact and cost-effec-
tiveness of new vaccines based on parameters such as population, disease incidence, vaccine
schedule, efficacy, and coverage, healthcare costs and vaccine program costs. More details on
UNIVAC are available elsewhere [13]. UNIVAC was developed to assist decision makers by
generating evidence around the use of new vaccines, including rotavirus vaccines, and has
been used in several cost-effectiveness studies to date [14,15].
Burden of disease
We assumed an overall incidence of rotavirus gastroenteritis in the under-five Palestinian pop-
ulation of 10,000 cases per 100,000 per year based on a systematic review and meta-analysis
[16]. We differentiated non-severe and severe episodes using results from another systematic
review and meta-analysis, applying proportions of severe and moderate diarrhea as reported
for EMRO [17]. To estimate the number of cases that receive treatment through an outpatient
visit or hospitalization, we made additional assumptions around treatment-seeking rates. We
assumed that 52.9% of cases would seek treatment in an outpatient setting based on the latest
Palestine Multiple Indicator Cluster Survey (MICS) [18] and that a larger proportion of severe
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cases would seek treatment in an inpatient setting (80%) based on expert opinion. Finally,
we used a recently published global review for disease event age distribution and a rotavirus-
related mortality rate of 2.03 deaths per 100,000 per year in children under five years, which is
the median value obtained from three different sources estimating rotavirus deaths [2,19,20].
DALY calculations are based on standard DALY weights and a duration of illness of three and
seven days for non-severe and severe rotavirus episodes, respectively [21,22]. All parameters
and input values used to model disease burden are displayed in Table 1 along with the low and
high inputs used in sensitivity analyses.
Vaccine efficacy, coverage, and timeliness
Our analysis assumes similar protective efficacy and waning for both vaccines, based on data
generated by a recent pooled analysis using all published rotavirus vaccine randomized control
trials [23]. We applied pentavalent vaccine coverage rates as reported by the MOH and vaccine
coverage timeliness as reported by the latest Palestine MICS [18,24]. Data input values used for
vaccine efficacy and coverage are available from Table 1.
Treatment costs
To estimate treatment costs, we modeled direct medical, direct non-medical, and indirect
costs linked to an episode of RVGE. Using data from a study estimating the unit costs of care
in public hospitals and primary healthcare centers in Palestine [25], we estimated direct medi-
cal costs linked to treating RVGE in inpatient and outpatient settings. To estimate direct medi-
cal costs for RVGE care in inpatient settings, we used the unit cost per patient day from this
study, which included salaries, operating costs, and overhead in the general surgery ward, the
closest fit among available datasets. Based on information received from the MOH, the average
length of stay for a child with diarrhea was two days. We further accounted for costs of labora-
tory tests (CBC, serum electrolytes, and stool analysis) and medicines (two IV Ringer lactate
and three packets of oral rehydration solution [ORS]) according to the standard protocol for
treating childhood diarrhea in Palestine. Costs for these supplies and drugs were based on unit
prices collected from the Palestinian central medical store. We used similar methods to esti-
mate direct medical cost in the outpatient setting, using unit cost per visit in primary health
care facilities [25] and accounting for a child receiving three packets of ORS. Based on the stan-
dard treatment protocol, we assumed no laboratory tests were done when a child presents with
non-severe diarrhea in an outpatient setting.
We also calculated direct non-medical costs based on expert opinion, including expenses
for transportation and food for the child and the caregiver. These costs were valued based on
local prices and accounted for the setting (inpatient or outpatient) where the child received the
care.
We further accounted for the productivity losses of the caregiver, which we valued using
the average daily wage in West Bank and Gaza, accounting for unemployment rates and for
the distribution of the labor force in each area [26]. We first calculated the daily loss of produc-
tivity distinctly for the West Bank and Gaza area. For this we multiplied the average daily wage
for employees with formal sector employment by the complement of the unemployment rate
(1 minus unemployment rate) as in the equation below.
Rate for employed population ¼ 1   rate for unemployed population
We then calculated an average daily loss of productivity factoring the distribution of the
labor population in West Bank and Gaza to estimate the average productivity value per day for
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Table 1. Study input parameters.
Rotavirus disease burden inputs
Base case value Low input High input Source
Annual incidence rates per 100,000 in under-5 population
Overall RVGE incidence 10,000 7,000 14,000 [16]
RVGE non-severe cases 8,224 6,160 11,373 [17]
RVGE non-severe visits 4,350 3,259 6,016 [18]
RVGE severe cases 1,776 839 2,627 [17]
RVGE severe visits 939.5 444 1,390 [18]
RVGE severe hospitalizations 1,421 555 2,102 Assumption
Severe RVGE deaths 2.03 0.84 4.88 [2,19,20]
Disease event age distribution
<1 month 0% - - [19]
<2 months 1%
<3 months 3%
<6 months 14%
<1 year 48%
<2 years 89%
<3 years 98%
<4 years 100%
<5 years 100%
DALY calculation
Non-severe RVGE
DALY weight 18.8% 12.5% 26.4 [21]
Duration of illness 3 days - - [22]
Severe RVGE
DALY weight 24.7% 16.4% 34.8% [21]
Duration of illness 7 days - - [22]
Vaccine efficacy, coverage, and timeliness
Base case value Low input High input Source
Dose 1 vaccine efficacy
2 weeks after vaccination 57.8% 45% 74% [23]
6 months after vaccination 48.6%
12 months after vaccination 44%
Dose 2 vaccine efficacy
2 weeks after vaccination 91.4% 89.9% 92.7% [23]
6 months after vaccination 76.8%
12 months after vaccination 69.5%
Dose 3 vaccine efficacy
2 weeks after vaccination 91.4% 89.9% 92.7% [23]
6 months after vaccination 76.8%
12 months after vaccination 69.5%
Vaccine coverage
Dose 1 99.5% - - [24]
Dose 2 99.5% - -
Dose 3 97.4% - -
Coverage timeliness
(Continued)
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Palestine. We assumed two days lost for inpatient care and two hours lost for outpatient care
(or 25% of daily productivity value).
Based on standard methods, we allocated direct medical costs to the health system cost while
direct non-medical and indirect were allocated to household costs. The sum of health system
and household costs is used for the societal perspective. To capture the costs of receiving care
in the private sector, we explored a 50% increase of direct medical costs in the sensitivity analy-
sis, based on information shared by MOH staff on the potential magnitude of cost differences
between public and private sector. Whereas all children under six years of age in Palestine are
covered through governmental insurance and have free access to healthcare in the MOH or
facilities run by the United Nations Relief and Works Agency for Palestine refugees (UNRWA),
private hospitals also operate, likely capturing a significant share of healthcare utilization.
Incremental health system costs
We evaluated the incremental financial and economic costs to the health system related to the
introduction of the rotavirus vaccine. The data to estimate these incremental costs were
obtained through primary and secondary data collection.
Table 1. (Continued)
Dose 1 [19]
Coverage at 1 month 0% - -
Coverage at 3 months 21% - -
Coverage at 6 months 97% - -
Coverage at 12 months 99.5% - -
Dose 2
Coverage at 1 month 0% - -
Coverage at 3 months 0% - -
Coverage at 6 months 99.5% - -
Coverage at 12 months 99.5% - -
Dose 3
Coverage at 1 month 0% - -
Coverage at 3 months 0% - -
Coverage at 6 months 15% - -
Coverage at 12 months 97.4% - -
Vaccine and commodities costs
Base case value Low input High input Source
ROTAVAC vaccine price $1 $0.85 $1.5 [31, 32]
ROTARIX vaccine price $4 - - [32]
Safety box unit price (100 dose volume) $0.64 - - [32]
International handling (as a % of vaccine price) 3.5% - - [32]
International delivery costs (per dose) [32]
ROTARIX $0.0264 - -
ROTAVAC $0.0249 - -
In-country logistics costs, port of entry to central store (per dose) [32]
ROTARIX $0.0290 - -
ROTAVAC $0.0173 - -
Wastage MoH
ROTARIX 0.3% - -
ROTAVAC 4.7% - -
Safety boxes 5% - -
https://doi.org/10.1371/journal.pone.0228506.t001
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Incremental supply chain and service delivery costs. To assess supply chain and service
delivery costs, primary data collection was carried out in West Bank and Gaza using structured
questionnaires in 20 health facilities providing immunization services, 6 health directorates
(district offices), and at the central store. We estimated the cost of supply chain and service
delivery for all vaccines used in the immunization program and used these data to estimate
the incremental economic costs of adding rotavirus vaccine into the immunization program
in Palestine. Main cost categories accounted for resources used by the immunization program
for cold chain storage (e.g., refrigerators, freezers, cold rooms), transportation of vaccines and
immunization supplies, waste disposal, and human resources time for immunization activities.
Financial costs account for actual expenditure on the goods and services purchased. These
would include purchases of new cold chain equipment, changes in the vaccine delivery fre-
quency or type of transport used, or new staff hired due to the vaccine introduction. We inter-
viewed MOH collaborators to gather information on whether the introduction of ROTARIX
and ROTAVAC vaccines had resulted in any such financial costs.
Economic costs account for the opportunity costs of resources, including existing resour-
ces that could have been used for alternative purposes. To estimate cold chain costs, we col-
lected information on the types of cold chain equipment available at each level of the supply
chain and combined this with secondary data. The cold chain costs included the annualized
capital costs for the existing cold chain and the annual energy costs for operating the cold
chain equipment. To estimate the cost per cm3 of vaccine storage, total costs for cold chain
at each facility were divided by the total vaccine storage capacity of the equipment, adjusted
for the utilization rate of the equipment.
To estimate transport costs, we collected information on whether vaccines and immuni-
zation supplies were delivered by each facility or collected, the types of vehicles used for the
delivery, the expenditures on fuel and maintenance, the number of trips made, and distance
traveled. These data were used to estimate transport costs, which include the annualized
capital costs for vehicles, and annual expenditures for fuel and maintenance of the vehicles.
Except for the five health facilities in Gaza, all other health facilities in the sample had vac-
cines delivered by the directorate. In order to avoid double-counting of transport costs, we
assumed that vaccines are typically delivered by the directorate and so transport costs are
only included at the directorate and central or territorial level. We estimated the cost per
cm3 transported by dividing the total transport costs by the volume of vaccines transported.
We adjusted transport costs to account for the fact that vaccines are delivered on the same
trip with immunization supplies at the directorate and with other non-immunization pro-
gram commodities at the central store. Immunization supplies are bulkier, with a typical
syringe having a volume of 30 cm3 compared to vaccines whose volumes typically range
from 1 to 4 cm3 per dose in multi-dose vials. We estimated that vaccines would account for
about 9% of the volume of commodities transported at the directorate and about 1.4% of
the volume transported at the central store.
These estimated cold chain and transport costs per cm3 were then multiplied by the volume
per dose of ROTARIX (17.12 cm3) and ROTAVAC (4.2 cm3) to estimate the incremental cold
chain and transport cost per dose for each vaccine.
WHO guidelines suggest that an incremental cost assessment should account for 15 min-
utes per dose of a new vaccine to capture the economic costs of time for vaccine administra-
tion and record-keeping [27]. This estimate is consistent with estimates from our analysis.
However, we also sought to account for the slight difference in administration time between
ROTARIX and ROTAVAC. Based on discussions with some of the nursing staff in West
Bank during the field testing of the questionnaires, we understood that ROTARIX is slightly
more challenging to administer, due to the larger volume given to the infant (1.5 ml)
Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness
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compared to ROTAVAC (0.5 ml). With ROTARIX, infants tend to regurgitate and there
may be need to spend time to make sure the infant gets the full dose; some infants may even
need a dose repeated. As a result, we therefore assumed a marginal time differential of 30
seconds for staff time between ROTARIX and ROTAVAC. A larger time differential is possi-
ble but the corresponding estimated costs at the health facility would fall within the facility
cost uncertainty range examined in the sensitivity analysis.
We estimated the total human resource costs at each level by multiplying the salary for
each staff by the percentage of time spent on immunization program-related activities and
summing this across the staff at the facility. The information on the time spent on immuni-
zation program-related activities was obtained from the costing interviews we conducted,
and average salaries by job level/grade were obtained from MOH and UNWRA. We then
estimated the cost per minute of staff time at each facility by dividing the total human costs
of all staff working in the immunization program at the facility by the estimated total time
spent on immunization related activities.
The health workers dispose the vials in the same safety boxes as sharps waste (all medical
waste were disposed in safety boxes). To estimate the cost per cm3 for waste disposal, we used
secondary data provided under the assumption that it costs NIS 5 (~US$1.40) per kilogram to
dispose of sharps waste [28]. We estimated the cost of waste disposal assuming 1 liter = 1 kilo-
gram, as per standard metric conversions, and estimated the waste disposal cost per cm3 and
per dose of each vaccine.
Introduction costs. To assess the costs linked to introducing ROTARIX in 2016 and the
additional costs linked to switching products in 2018, we conducted key informant interviews
within the Department of Public Health within the MOH to identify the activities that occurred
with the rotavirus vaccine introduction and identify data sources. Respondents from UNRWA
and UNICEF, active partners of the vaccination program, were also interviewed and provided
information on the activities conducted and corresponding expenditure data. Introduction
costs were mainly collected from invoices and expenditure reports provided by the MOH
immunization team and other partners. In line with WHO guidelines for estimating costs of
new vaccine introduction [29], we used an incremental costing approach to assess the cost of
activities that took place and investments for the addition of the rotavirus vaccine to the routine
immunization program. For each activity or investment, we estimated both financial and eco-
nomic costs. We gathered introduction costs separately for Gaza and the West Bank.
The main cost categories assessed included training of MOH staff and communication
materials. While financial costs were retrieved from financial reports and invoices, economic
costs were calculated by valuing the staff time spent on training, using information provided
by MOH directors on duration of training, number and type of staff trained, and types of
training. Introduction costs were collected for the introduction of ROTARIX in 2016 and for
the switching from ROTARIX to ROTAVAC in 2018.
In order to combine introduction costs with other recurrent costs (supply chain and service
delivery costs), we annualized the figure obtained through secondary data collection. For this
process we assumed a 3-year period during which introduction cost benefits last. For annualiz-
ing the introduction costs, we performed simple annualization without discounting to annual-
ize the introduction costs for training and communication over a three-year period.
Vaccine procurement costs
Procurement cost data were collected from the local UNICEF office using reports of each ship-
ment of rotavirus that entered Palestine from late-2015 to mid-2018. For the analysis, we used
a different vaccine price for ROTAVAC because of the current uncertainty over the final price
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that the government will be able to access. In our base-case scenario, we used a price of US$1
per dose of ROTAVAC, the price paid by RVF while the organization was supporting the rota-
virus vaccination program [30]. In an alternative price scenario, we used a lower price ($0.85),
as offered to Gavi countries [31], as well as a higher price ($1.50) in order to reflect a range of
possible prices that the government of Palestine may have to pay. For ROTARIX, we used the
price paid at the time the vaccine was used ($4) [32]. In addition to price paid, we also collected
information on international handling and transportation, including in-country transporta-
tion from port of entry to the central store. We used reported wastage data and a series of addi-
tional parameters, including international handling and transportation, to model vaccine and
commodities costs as displayed in Table 1.
Sensitivity analysis
To account for uncertainty in some of the parameters used in the analysis, we ran sensitivity
analyses covering a range of more and less favorable scenarios. We looked at a lower and
higher rotavirus disease burden, higher and lower vaccine efficacy, higher and lower incre-
mental health system costs, and higher and lower vaccine price for ROTAVAC. Low and
high values used in the sensitivity analysis and their reference are available from Table 1.
In addition to sensitivity analysis using different scenarios, we also undertook probabilistic
sensitivity analysis on a series of parameters, running the analysis 1,000 times to create a cost-
effectiveness acceptability curve for the scenario with ROTAVAC. Parameters included in the
probabilistic sensitivity analysis are disease burden, DALY weights, vaccine efficacy, vaccine
waning, vaccine price, health system costs per dose, and healthcare costs. Low and high data
value for each parameter and distributions used are available in supplementary files.
Cost-effectiveness threshold
To interpret our results, we used a cost-effectiveness or willingness-to-pay threshold of one
times the GDP per capita, $3,095 [33], in line with practice reported by local experts for similar
economic evaluations performed by the Palestinian MOH.
Results
Treatment costs
We estimated that treating one case of severe RVGE in an inpatient setting has a direct medical
cost of $173.85. Direct non-medical costs are $28.04 and indirect costs are $35.59, which add
up to a total societal perspective cost of $237.48. Treating RVGE in outpatient setting has a
much lower cost, with direct medical costs amounting to $7.63 and a total societal perspective
cost of $21.43. S1 Table in supplementary material displays the values resulting from our
calculations.
Incremental health system costs
Incremental supply chain and service delivery costs. The introduction of ROTARIX
and ROTAVAC vaccines did not result in any new purchase of cold chain equipment at any
level of the supply chain. The system also had enough transport capacity to accommodate both
vaccine introductions. Because rotavirus vaccines were added into the EPI schedule and the
schedule aligns with other vaccines already included in the schedule, no new visits were needed
and no new staff were hired. Hence, there were no incremental financial costs for cold chain,
transport, or human resources associated with the introduction of either ROTARIX or ROTA-
VAC. We estimated the incremental economic costs for the supply chain and service delivery
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to average $2.70 per dose for ROTARIX compared to an average of $2.36 for ROTAVAC
(Table 2). The incremental economic costs were larger for ROTARIX than ROTAVAC
because of the larger volume per dose. The economic costs per dose were also larger at the
lower levels of the supply chain because of the relatively higher fixed costs for cold chain and
health worker time spent on service delivery, relative to the volume of vaccines used.
Introduction costs. Economic costs associated with the introduction of ROTARIX in
2016 amounted to a total of $296,263. This is higher than the total economic cost linked with
switching to ROTAVAC in 2018, amounting to $159,524. This is explained by the higher
intensity of training activities related to introducing rotavirus vaccine for the first time. Train-
ing sessions were longer and targeted a higher number of individuals in 2016. Similarly, fewer
communication materials were developed for the switch to ROTAVAC. Because of this cost
difference, we elected to apply introduction costs of ROTARIX to both vaccines while doing
the cost-effectiveness analysis. This allowed for a fair comparison assuming that if Palestine
had introduced ROTAVAC as the first rotavirus vaccine, they would likely face similar intro-
duction costs to what was required for ROTARIX. S2 Table in supplementary materials dis-
plays details of the financial and economic introduction costs for both vaccines per area.
When adjusted to 2018 US$, annualized and combined as per dose value, the introduction
cost per dose was $0.35 for ROTARIX and $0.24 for ROTAVAC.
Impact and cost-effectiveness
Based on the assumption of similar efficacy for the two rotavirus vaccines, health and eco-
nomic benefits reported in Table 3 are applicable for both ROTARIX and ROTAVAC. Over
ten years, rotavirus vaccination in Palestine has the potential to avert approximately 468,000
non-severe RVGE cases, 101,000 severe RVGE cases, and about 100 deaths. This represents
potential savings on treatment costs of approximately $14 million for the health system and
approximately $22 million for the society.
Table 2. Incremental economic supply chain costs associated with ROTARIX and ROTAVAC.
ROTARIX ROTAVAC—5 dose vials
Cost category Average Min Max Average Min Max
Estimated incremental economic costs per dose at the health facility level
Cold chain $0.28 $0.04 $1.41 $0.07 $0.01 $0.34
Waste disposal $0.02 $0.01
Human resource $2.01 $1.53 $2.32 $1.95 $1.47 $2.24
Total $2.32 $1.59 $3.75 $2.02 $1.49 $2.59
Estimated incremental economic costs per dose at the directorate level
Cold chain $0.03 $0.0330 $0.05 $0.024 $0.006 $0.091
Transport $0.022 $0.0138 $0.044 $0.005 $0.003 $0.011
Human resource $0.30 $0.10 $0.50 $0.30 $0.10 $0.50
Total $0.35 $0.15 $0.59 $0.33 $0.11 $0.60
Estimated incremental economic costs per dose at the central store
Cold chain $0.0114 - - $0.012 - -
Transport $0.003 - - $0.003 - -
Human resource $0.01 - - $0.001 - -
Total $0.03 - - $0.016 - -
Total incremental economic costs per dose costs at all levels of the supply chain
Total $2.695 $1.77 $4.37 $2.362 $1.62 $3.21
Total incremental economic costs per child
Total $5.39 $3.54 $8.74 $7.09 $4.86 $9.63
https://doi.org/10.1371/journal.pone.0228506.t002
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The 10-year vaccination program costs vary depending on which vaccine and price are con-
sidered. It ranges from a high of $19 million with ROTARIX at $4 per dose to a low of $14.8
million with ROTAVAC at $0.85 per dose. In our base case scenario with ROTAVAC at $1
per dose, the vaccination program cost is $15.5 million.
As shown in Table 3, the incremental cost-effectiveness ratio from the health system per-
spective is estimated at $1,254 with ROTARIX and $353 for ROTAVAC compared to no vacci-
nation program. From the societal perspective, both vaccines were cost-saving in our base-case
scenario compared to no vaccination program. Assuming a similar health impact of both vac-
cines and with lower vaccination program costs for ROTAVAC, switching from ROTARIX to
ROTAVAC was a cost-saving alternative for Palestine.
Sensitivity analysis
The different scenarios explored in the sensitivity analyses show that in many of the scenar-
ios, rotavirus vaccination with either vaccine is a cost-saving intervention in Palestine; i.e.,
rotavirus vaccination is both more effective (averts more DALYs) and costs less than no vac-
cination. Only when we assume a very low burden of disease was rotavirus vaccine not cost-
effective; i.e., where the cost per DALY averted would be above the threshold of one times
the GDP per capita. ROTAVAC shows better value for money over ROTARIX in all scenar-
ios analyzed, including when accounting for a higher vaccine price of $1.50 per dose. Disease
Table 3. Health and economic outcomes (10 cohorts vaccinated over the period 2016–2025, costs discounted).
Health outcomes
Total non-severe cases <5 yrs averted 468,167
Total severe cases <5 yrs averted 101,112
Total outpatient visits averted 301,148
Total hospitalizations averted 80,889
Total deaths <5 yrs averted 102
DALYs (discounted) averted 3,921
Health system treatment costs
Outpatient visit costs averted $1,983,909
Hospitalization costs averted $12,141,801
Total health system treatment costs averted $14,125,710
Societal treatment costs
Outpatient visit costs averted $5,572,106
Hospitalization costs averted $16,585,763
Total societal treatment costs averted $22,157,869
Vaccine program costs
With ROTARIX (at $4 per dose) $19,044,961
With ROTAVAC (at $1 per dose) $15,510,482
With ROTAVAC (at $0.85 per dose) $14,826,329
With ROTAVAC (at $1.5 per dose) $17,790,994
Cost per DALY averted (ROTAVAC at $1 per dose)
ROTARIX compared to no vaccine (health system perspective) $1,254
ROTARIX compared to no vaccine (societal perspective) Cost-saving (-$794)
ROTAVAC compared to no vaccine (health system perspective) $353
ROTAVAC compared to no vaccine (societal perspective) Cost-saving (-$1,695)
ROTAVAC compared to ROTARIX (health system perspective) Cost-saving (-$901)
ROTAVAC compared to ROTARIX (societal perspective) Cost-saving (-$901)
https://doi.org/10.1371/journal.pone.0228506.t003
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burden and healthcare costs are the two main drivers of uncertainty. Fig 1 displays the
results in terms of discounted cost per DALY averted for all scenarios explored.
From the health system perspective, ROTAVAC has a 90% chance of being cost-effective at
a threshold of $1,500 per DALY averted (note that $1,500 is 50% of the GDP per capita). At a
threshold of $3,000 per DALY averted (i.e., the threshold used in most of the results reported
above), the probability of ROTAVAC to be a cost-effective intervention in Palestine is 100%.
The cost-effectiveness acceptability curve displayed in Fig 2 shows the results of the probabilis-
tic sensitivity analysis.
Discussion
From the health system perspective, rotavirus vaccination with either ROTARIX or ROTA-
VAC is a cost-effective intervention in Palestine compared to no vaccination, averting a share
of the rotavirus disease burden and generating substantial savings on healthcare costs. When
accounting for averted healthcare-related costs for households, using either vaccine is a cost-
saving intervention, highlighting the economic burden rotavirus represents for households
and the health system in Palestine. Other studies conducted in the EMRO region have also
found that rotavirus vaccine introduction is cost-effective or cost-saving compared to no vacci-
nation [14,36,37]. When evaluating the switch, ROTAVAC presents an economic advantage
over ROTARIX and shifting from ROTARIX to ROTAVAC was a cost-saving option from
both the health system and societal perspectives. Savings due to a much lower price per dose
for ROTAVAC compared to ROTARIX outweigh any cost disadvantages resulting from hav-
ing a three-dose rather than two-dose schedule. The price of ROTARIX must fall to approxi-
mately $2.75 in Palestine to achieve a cost-effectiveness ratio comparable to ROTAVAC.
Financial costs associated with the introduction of rotavirus vaccination, including costs
related to training of health care workers and printing of communication materials, were mod-
est. There were no financial costs incurred for the supply chain and service delivery since the
health system had adequate resources to accommodate the rotavirus vaccine introduction and
switch. However, when accounting for the opportunity costs of using existing human
resources and vaccine storage equipment and transport, economic costs of the rotavirus vac-
cine introduction and use are much higher. Other studies have estimated incremental costs for
rotavirus vaccine introduction of $2.15 in Zambia and $0.54 in Rwanda [34,35]. Differences in
estimates may be due to different country contexts, introduction modalities, and methodology
used.
While shifting to ROTAVAC, Palestine managed to keep open vial vaccine wastage rates
comparatively low (4.7%) for a multi-dose vaccine presentation. This was achieved by increas-
ing session sizes though aggregation. The reported wastage rate in Palestine is much lower
than expected for similar multi-dose products, which typically have wastage rates of 25–30%
[31,38]. This finding from Palestine shows the feasibility of reaping the benefits attributable to
the lower price per dose associated with a multi-dose vial presentation while minimizing the
open vial wastage rate.
Palestine was able to smoothly transition from one rotavirus vaccine product to another,
even though vaccine price and other programmatic considerations such as the storage condi-
tions, number of doses, and open vial wastage rates of the two vaccines are different. As other
countries consider switching between rotavirus vaccine products, the results from Palestine
can provide evidence on the cost tradeoffs of these two vaccine presentations and how these
tradeoffs impact cost-effectiveness.
This study has several limitations. We were not able to fully leverage local surveillance data
to model rotavirus disease burden in the countries. We attempted to collect data for the year
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Fig 1. Discounted cost per DALY averted for ROTARIX and ROTAVAC under different scenarios. For each scenario, the first result
presented is from the health system perspective and the second result is from the societal perspective.
https://doi.org/10.1371/journal.pone.0228506.g001
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before vaccine introduction to inform our estimated rotavirus incidence rates in the absence
of vaccination, but found incomplete data sets from the health information system on hospital-
ized diarrhea cases. The existing data showed that, in 2015, only a share of the hospitals had
electronic reports, and paper records from that time were missing. We also experienced diffi-
culties with the lack of standardization in how diarrhea cases were reported. In Gaza, services
are provided through the MOH and UNRWA, but until recently, the two providers reported
data for different age groups (0 to 3 years vs. 0 to 5 years), not allowing us to generate consis-
tent numbers for children under a single age span. Finally, data on primary healthcare visits
for diarrhea were reported for the entire population, not differentiated by specific age groups.
We addressed these data limitations by using publicly available global and regional data. To
address the uncertainty around these estimates and how well they represent the rotavirus bur-
den in Palestine, we explored fairly large uncertainty ranges in sensitivity analysis.
UNIVAC is a static model which likely underestimates the benefits of vaccination by not
accounting for potential herd effects. Others have studied the effect of rotavirus vaccination
using dynamic models but findings from different countries tend to show uncertainty around
the scale and duration of predicted herd effects [13].
Fig 2. Cost-effectiveness acceptability curve.
https://doi.org/10.1371/journal.pone.0228506.g002
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In this analysis, we assumed ROTARIX and ROTAVAC to have similar efficacy, leading to
an equivalent health impact. There is currently limited information on ROTAVAC efficacy
outside the Indian population, although field effectiveness studies are underway. In India, a
randomized, double-blind, placebo-controlled trial showed efficacy levels of 56% in 12-month
olds [39].
Of note, a private pediatric hospital in southern Palestine began conducting rotavirus sur-
veillance several years prior to the introduction of rotavirus vaccine and has continued these
activities through the transition to ROTAVAC. This monitoring showed a decrease in rotavi-
rus prevalence following introduction of ROTARIX [10]. Our assumption of similar efficacy
for the two vaccines may be confirmed in the near future as more recent epidemiological sur-
veillance data become available.
Because of the paucity of data, we do not differentiate vaccine efficacy between severe and
non-severe rotavirus disease. Although this may overestimate the impact on non-severe dis-
ease, it would remain within the bounds of our uncertainty range and has little influence on
results.
To our knowledge, this is the first economic analysis of the use of ROTAVAC outside of
India using empirical data. The Palestine experience can be considered by countries in their
decision-making processes around rotavirus vaccination, particularly in the context of the
availability of other new rotavirus vaccine products. Despite the potential challenges with dis-
ease burden or cost data availability for modeling, countries should consider systematically
assessing multiple aspects beyond vaccine price when comparing the health and economic
value of several products in order to fully account for all characteristics. However, for countries
not eligible for Gavi support who may be exploring the financial sustainability of their immu-
nization programs, our analysis suggests that vaccine price is a critical variable and that their
choice of vaccine should be re-assessed when new, low-cost products become available.
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